Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
EBSthis companyEmergent BioSolutions Inc.	$6.03	12.61×	1.27×	0.89×	4.32×	-48.4%	47.2%	14.8%	7.1%	10.1%	5.9%	23.7%	1.09×	1.54×	1.86×	5.01×	0.0%	4	0.4	1	C-
AQSTAquestive Therapeutics, Inc.	$3.66	-8.5×	-23.41×	17.69×	-12.07×	-157.6%	61.5%	-156.4%	-188.1%	248.9%	-56.0%	-6.7%	-3.9×	-0.16×	-4.07×	3.14×	0.0%	3	-3.77	2	C
CRVSCorvus Pharmaceuticals, Inc.	$11.10	-40.53×	9.93×	0×	-39.82×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-69.1%	-5.4%	0.02×	0.24×	0×	6.21×	0.0%	2	32.84	2	C
OLMAOlema Pharmaceuticals, Inc.	$7.24	-13.37×	4.55×	0×	-13.14×	-93.1%	0.0%	0.0%	0.0%	-33.9%	-37.0%	-6.7%	0×	0.29×	0×	9.95×	0.0%	2	4.21	2	C+
ORGOOrganogenesis Holdings Inc.	$0.82	32.38×	1.51×	1.17×	9.41×	422.9%	75.6%	9.9%	6.6%	8.5%	8.5%	-3.7%	0.31×	0.53×	0×	3.62×	0.0%	2	1.23	2	C+
RIGLRigel Pharmaceuticals, Inc.	$41.32	2.1×	1.97×	2.62×	5.95×	-171.8%	93.3%	42.6%	124.7%	93.8%	28.2%	9.8%	0.14×	0.1×	17.14×	2.42×	0.0%	4	4.57	4	A
Peer median	—	-8.5×	1.97×	1.17×	-12.07×	-99.8%	61.5%	0.0%	0.0%	8.5%	-37.0%	-5.4%	0.02×	0.24×	0×	3.62×	0.0%	2	4.21	2	—